GLP-1 treatment prolongs digestion, helping to maintain your feeling of fullness for a longer period
This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease, suggesting they have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or CKD [chronic kidney disease], said lead author Sunil Badve, professorial fellow at The George Institute for Global Health and UNSW Sydney
More notably, his alcohol consumption underwent a drastic reduction: at baseline, he consumed ~15 alcoholic drinks weekly, with frequent binge episodes (9 or more drinks in a single sitting)
BPC-157 + TB-500 Blend From 71.99 Glow Blend (BPC-157 + GHK-Cu + TB-500) 70mg 101.99
Practices that only focus on one area are leaving opportunities and revenue on the table
Join Trial Testing New Drug for Weight Management A clinical trial is recruiting adults with type 2 diabetes to test a new long-lasting amylin drug for weight management